Trade Names:Cerezyme- Powder for injection, lyophilized 212 units- Powder for injection, lyophilized 424 units
Imiglucerase catalyzes the hydrolysis of glucocerebroside to glucose and ceramide.
Vd is 0.09 to 0.15 L/kg. Steady state achieved by 30 min during 1 h infusion.
The t ½ is 3.6 to 10.4 min. Plasma Cl ranges from 9.8 to 20.3 mL/min/kg.
Long-term enzyme replacement therapy for pediatric and adult patients with confirmed diagnosis of Type I Gaucher disease that results in at least 1 of the following conditions: anemia, bone disease, hepatomegaly, splenomegaly, or thrombocytopenia.
IV Dosage is individualized. Initial dose ranges from 2.5 units/kg 3 times/wk to 60 units/kg once every 2 wk. Dosage adjustments should be made based on achievement of therapeutic goals as assessed by routine comprehensive evaluations of the patient's clinical manifestations.
Store vials in refrigerator (36° to 46°F). Reconstituted solution is stable for up to 12 h when stored in refrigerator or at room temperature not exceeding 77°F. Diluted solution is stable for up to 24 h if refrigerated.
None well documented.
None well documented.
Dizziness, fatigue, headache (6%).
Rash (6%); flushing, pruritus (postmarketing).
Abdominal pain, diarrhea, nausea, vomiting (6%).
Hypersensitivity symptoms, including angioedema, chest discomfort, coughing, cyanosis, dyspnea, flushing, hypotension, pruritus, urticaria (6%); anaphylactoid reaction (less than 2%).
Coughing, dyspnea (postmarketing).
Chills (6%); fever (postmarketing).
Periodically monitor for immunoglobulin G (IgG) antibody formation during first year of treatment.
Category C .
Safety and efficacy established in patients between 2 and 16 yr of age. Safety and efficacy in patients less than 2 yr of age not established.
Use with caution in patients who have exhibited symptoms of hypersensitivity to imiglucerase. Anaphylactoid reactions have been reported but most patients successfully continued treatment after reduction in infusion rate and pretreatment with antihistamines and/or corticosteroids.
IgG antibodies to imiglucerase developed in 15% of treated patients during first year of therapy, most within 6 mo of treatment and rarely after 12 mo. Approximately 46% of patients with detectable IgG antibodies experienced hypersensitivity symptoms.
Imiglucerase should be used only by health care professionals knowledgeable in the management of patients with Gaucher disease.
Use with caution in patients who developed antibodies or symptoms of hypersensitivity during previous treatment with alglucerase.
Pulmonary hypertension and pneumonia have been observed in less than 1% of treated patients, but a relationship with imiglucerase has not been established. Evaluate patients with respiratory symptoms in absence of fever for presence of pulmonary hypertension.
No reports of obvious toxicity at doses up to 240 units/kg every 2 wk.
Copyright © 2009 Wolters Kluwer Health.